Real-World Evidence Toolkit (Target Trial, Bias, Fitness-for-Purpose)

Toolkit
Real-World Evidence Toolkit
A practical toolkit for real-world evidence workflows, including target-question framing, fit-for-purpose data prompts, time-alignment checks, bias diagnostics, and transparent reporting language.
Published

April 23, 2026

Modified

June 9, 2026

Executive Summary

This toolkit is a reusable framework for real-world evidence analysis when clinical, registry, EHR, or operational data are being used to support analytic claims.

It includes:

  • target-question prompts
  • fit-for-purpose data checks
  • time-zero and eligibility templates
  • common bias checklists
  • design and estimand prompts
  • reviewer-facing reporting language

Real-world evidence is not just observational analysis by another name. It requires explicit attention to how data were generated, what question is being asked, whether the data are fit for that purpose, and what biases remain likely after analysis (Hernán and Robins 2020; Fang et al. 2020).

1. Start With the Actual Question

A real-world evidence workflow should begin by stating the question in operational language.

At minimum, document:

  • decision context: regulatory, clinical, quality-improvement, operational, or exploratory?
  • target population: who is the evidence intended to inform?
  • intervention/exposure: what is being compared?
  • outcome: what endpoint matters?
  • timing: when does eligibility and follow-up begin?

Without that structure, many RWE analyses become post hoc summaries with unclear relevance.

2. Fit-for-Purpose Data Checklist

A central RWE question is not just whether data exist, but whether they are fit for the analytic purpose.

Create a simple worksheet:

fit_for_purpose_table <- tibble::tribble(
  ~domain, ~question, ~status, ~notes,
  "Eligibility", "Can the target cohort be identified reproducibly?", "Review", "Need explicit inclusion logic",
  "Exposure", "Is timing of treatment or intervention captured?", "Review", "Check order relative to baseline",
  "Outcome", "Is outcome ascertainment sufficiently complete?", "Review", "Potential transfer-related missingness",
  "Covariates", "Are major confounders measured before treatment?", "Review", "Need physiology at index time"
)

fit_for_purpose_table
# A tibble: 4 × 4
  domain      question                                          status notes    
  <chr>       <chr>                                             <chr>  <chr>    
1 Eligibility Can the target cohort be identified reproducibly? Review Need exp…
2 Exposure    Is timing of treatment or intervention captured?  Review Check or…
3 Outcome     Is outcome ascertainment sufficiently complete?   Review Potentia…
4 Covariates  Are major confounders measured before treatment?  Review Need phy…

A dataset can be rich and still not be fit for the estimand being claimed (Fang et al. 2020).

3. Define Time Zero Explicitly

Many RWE failures are time-alignment failures.

Before modeling, state:

  • when does follow-up start?
  • when does treatment become eligible?
  • when is a patient considered “treated”?
  • how are immortal time and delayed eligibility avoided?

If time zero is vague, even a sophisticated adjustment strategy can mislead (Hernán and Robins 2016, 2020).

4. Eligibility and Cohort Construction Template

cohort_definition <- tibble::tribble(
  ~step, ~rule, ~reason,
  1, "Identify all eligible encounters in the source system", "Define source population",
  2, "Apply explicit inclusion criteria", "Operationalize target cohort",
  3, "Apply exclusion criteria known before time zero", "Avoid conditioning on future information",
  4, "Assign time zero consistently", "Ensure aligned follow-up"
)

cohort_definition
# A tibble: 4 × 3
   step rule                                                  reason            
  <dbl> <chr>                                                 <chr>             
1     1 Identify all eligible encounters in the source system Define source pop…
2     2 Apply explicit inclusion criteria                     Operationalize ta…
3     3 Apply exclusion criteria known before time zero       Avoid conditionin…
4     4 Assign time zero consistently                         Ensure aligned fo…

One of the easiest mistakes in RWE is to create the cohort with information that would not have been available at the moment follow-up is supposed to begin.

5. Common Bias Checklist

Real-world evidence workflows should explicitly consider at least these threats:

  • confounding by indication
  • selection into the analytic sample
  • immortal time bias
  • outcome ascertainment differences
  • differential missingness
  • site or era drift
  • measurement error in key covariates

A useful toolkit prompt is to write one sentence for how each threat might appear in the current study.

6. Descriptive Design Table

Before modeling, produce a design table rather than only a baseline characteristics table.

design_table <- tibble::tribble(
  ~component, ~description,
  "Target population", "All eligible patients meeting inclusion criteria at index encounter",
  "Time zero", "Earliest moment all cohort members become eligible for exposure comparison",
  "Exposure strategy", "Observed treatment strategy as recorded in source data",
  "Outcome window", "Primary outcome assessed through prespecified follow-up period",
  "Censoring", "Loss to follow-up, discharge, transfer, or administrative end of study"
)

design_table
# A tibble: 5 × 2
  component         description                                                 
  <chr>             <chr>                                                       
1 Target population All eligible patients meeting inclusion criteria at index e…
2 Time zero         Earliest moment all cohort members become eligible for expo…
3 Exposure strategy Observed treatment strategy as recorded in source data      
4 Outcome window    Primary outcome assessed through prespecified follow-up per…
5 Censoring         Loss to follow-up, discharge, transfer, or administrative e…

This helps keep the analysis anchored to design logic rather than only model output.

7. Target Trial Prompt

When the question is causal, it is often helpful to describe the hypothetical trial being emulated (Hernán and Robins 2016, 2022).

A simple target-trial prompt includes:

  • eligibility criteria
  • treatment strategies
  • assignment procedure
  • follow-up start
  • outcome definition
  • estimand
  • analysis plan

If the observational design cannot approximate these elements, then causal language should usually be more restrained.

8. Minimal Outcome-Rate and Missingness Summary

rwe_summary <- function(df, outcome_var) {
  tibble::tibble(
    n = nrow(df),
    outcome_rate = mean(df[[outcome_var]] == 1, na.rm = TRUE),
    pct_outcome_missing = mean(is.na(df[[outcome_var]]))
  )
}

# rwe_summary(data, "outcome")

In real-world data, missingness is often part of the evidence structure, not just a nuisance to clear away.

9. Design-Aware Reporting Checklist

Minimum prompts:

  • source data and capture process described
  • cohort-construction logic stated explicitly
  • time zero defined clearly
  • analytic target identified as predictive, descriptive, or causal
  • fit-for-purpose data limitations discussed
  • major likely biases named directly
  • missing-data handling justified
  • transportability limits acknowledged

Transparent design reporting is part of what makes RWE interpretable (Fang et al. 2020).

10. Reviewer-Facing Language

Use language like this in methods or appendices:

This analysis used real-world data to address a clinically relevant question under routine care conditions. Because the source data were not generated through randomized assignment, we first defined the target cohort, time zero, outcome window, and analytic purpose before modeling. We then evaluated whether the data were fit for the intended question and explicitly considered likely threats to validity such as confounding, time-alignment problems, missingness, and differential ascertainment (Hernán and Robins 2020; Fang et al. 2020).

NoteWhere This Shows Up in AI/ML

The FDA’s real-world evidence program evaluates whether RWE from EHR, registry, and claims data can support regulatory decisions — and MAVEN-era analyses that emulate clinical trials using observational DoDTR and MHS GENESIS data are producing RWE in the regulatory sense, not just the academic sense. This means those analyses must meet the methodological standards the FDA has articulated: pre-specified analysis plans, documented confounding control, and explicit transportability assessments. An RWE study that does not pre-specify its primary analysis and confounding control strategy before accessing the data cannot credibly distinguish a true treatment effect from researcher degrees of freedom. The DoD’s investment in linked DoDTR-GENESIS infrastructure creates the opportunity for RWE at a scale few trauma systems can match — but only if the analytical methods are rigorous enough to meet the evidentiary bar.

11. Closing

A good real-world evidence workflow is not defined by whether the data are large. It is defined by whether the question, design, timing, and limitations are made explicit enough that the resulting evidence can be interpreted honestly.

Series Callout

Note

This post is part of a broader Toolkit Series for Applied Statistics, AI, and Clinical Analytics:

  • Bayesian Workflow Toolkit
  • Calibration Toolkit
  • Missing Data Toolkit
  • Rare Events Toolkit
  • Causal Inference Toolkit
  • Survival Analysis Toolkit
  • Prediction Modeling Toolkit
  • Real-World Evidence Toolkit
  • OMOP and Interoperability Toolkit
  • Trauma Registry Analytics Toolkit

Series: Toolkit

← Prediction Modeling Toolkit (Validation, Calibration, Reporting)  |  OMOP and Interoperability Toolkit (Mapping, Metadata, Governance) →

References

Fang, Yixin, Hongwei Wang, and Weili He. 2020. “A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.” Therapeutic Innovation & Regulatory Science 54 (4): 749–57. https://doi.org/10.1007/s43441-019-00008-2.
Hernán, Miguel A., and James M. Robins. 2016. “Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.” American Journal of Epidemiology 183 (8): 758–64. https://doi.org/10.1093/aje/kwv254.
Hernán, Miguel A., and James M. Robins. 2020. Causal Inference: What If. Chapman; Hall/CRC.
Hernán, Miguel A., and James M. Robins. 2022. “Target Trial Emulation: A Framework for Causal Inference from Observational Data.” JAMA 328 (24): 2446–47. https://doi.org/10.1001/jama.2022.21383.